Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway

被引:30
|
作者
Mirlashari, Mohammad Reza [1 ]
Randen, Ingrid [1 ,2 ]
Kjeldsen-Kragh, Jens [1 ,2 ]
机构
[1] Oslo Univ Hosp, Dept Immunol & Transfus Med, N-0407 Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
关键词
Glycogen synthase kinase-3; Leukemia; Apoptosis; Mitochondria membrane potential; beta-Catenin; SMALL-MOLECULE INHIBITORS; DRUG-INDUCED APOPTOSIS; COLON-CANCER CELLS; BETA-CATENIN; NEURONAL APOPTOSIS; GENE-TRANSCRIPTION; CASPASE ACTIVATION; DNA-DAMAGE; LITHIUM; EXPRESSION;
D O I
10.1016/j.leukres.2011.11.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The roles of glycogen synthase kinase-3 (GSK-3) in cell survival and apoptosis are controversial. We examined the effect of a specific GSK-3 inhibitor (SB-415286) on the regulation of leukemic cells proliferation and apoptosis. SB-415286 (40 mu M) induced cell growth inhibition, beta-catenin stabilization, cell cycle arrest in G(2)/M phase, cyclin B1 downregulation, and apoptosis in leukemic cell lines KG1a, K562, and CMK. Blocking the death receptor pathway by using a specific inhibitor of caspase-8, did not inhibit SB-415286-induced apoptosis. This indicates that activation of caspase-8 is part of the intrinsic apoptotic pathway and occurs downstream of mitochondria membrane potential depolarization mediated by other caspases. Furthermore, we found that depolarization of mitochondria membrane caused by GSK-3 inhibition is regulated by dephosphorylation of anti-apoptotic protein Bcl-2 and downregulation of Bcl-xL. Thus, inhibition of GSK-3-induced apoptosis of leukemic cells could be an attractive target for treatment of leukemia. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:499 / 508
页数:10
相关论文
共 50 条
  • [1] Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Induces Apoptosis In Leukemic Cells through Mitochondria-Dependent Pathway
    Mirlashari, Mohammad Reza
    Randen, Ingrid
    Kjeldsen-Kragh, Jens
    BLOOD, 2010, 116 (21) : 1190 - 1190
  • [2] Regulation of Autophagy by the Glycogen Synthase Kinase-3 (GSK-3) Signaling Pathway
    Pan, Hsuan-Yeh
    Valapala, Mallika
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [3] Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis
    Ibrahim, Samar H.
    Akazawa, Yuko
    Cazanave, Sophie C.
    Bronk, Steven F.
    Elmi, Nafisa A.
    Werneburg, Nathan W.
    Billadeau, Daniel D.
    Gores, Gregory J.
    JOURNAL OF HEPATOLOGY, 2011, 54 (04) : 765 - 772
  • [4] Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Attenuates Hepatocyte Lipoapoptosis
    Ibrahim, Samar H.
    Akazawa, Yuko
    Cazanave, Sophie
    Bronk, Steven F.
    Elmi, Nafisa
    Billadeau, Daniel D.
    Gores, Gregory J.
    GASTROENTEROLOGY, 2010, 138 (05) : S774 - S774
  • [5] Regulation of glycogen synthase kinase-3 beta (GSK-3β) by the Ala pathway in gliomas
    Atkins, Ryan J.
    Dimou, James
    Paradiso, Lucy
    Morokoff, Andrew P.
    Kaye, Andrew H.
    Drummond, Katharine J.
    Hovens, Christopher M.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2012, 19 (11) : 1558 - 1563
  • [6] 25-Hydroxycholesterol induces mitochondria-dependent apoptosis via activation of glycogen synthase kinase-3β in PC12 cells
    Choi, Y. K.
    Kim, Y. S.
    Choi, I. Y.
    Kim, S. -W.
    Kim, W. -K.
    FREE RADICAL RESEARCH, 2008, 42 (06) : 544 - 553
  • [7] Glycogen synthase kinase-3 (GSK-3): A kinase with exceptional therapeutic potential
    Benbow, JW
    Helal, CJ
    Kung, DW
    Wager, TT
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 135 - 147
  • [8] Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging
    Pandey, Mukesh K.
    DeGrado, Timothy R.
    THERANOSTICS, 2016, 6 (04): : 571 - 593
  • [9] Expression and localization of glycogen synthase kinase-3 (GSK-3) in mouse
    Yao, HB
    Shaw, PC
    Wan, DCC
    FASEB JOURNAL, 2001, 15 (04): : A547 - A547
  • [10] Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic
    Medina, Miguel
    Castro, Ana
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2008, 11 (04) : 533 - 543